• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Commun . Antigen persistence and TLR stimulation contribute to induction of a durable HIV-1-specific neutralizing antibody response

tetano

Editor, Senior Moderator
Nat Commun


. 2025 Jun 3;16(1):5162.
doi: 10.1038/s41467-025-60481-2. Antigen persistence and TLR stimulation contribute to induction of a durable HIV-1-specific neutralizing antibody response

Kenta Matsuda[SUP] 1 [/SUP], Mitra Harrison[SUP] 1 [/SUP], Eleanor Wettstein[SUP] 1 [/SUP], Jessica Pederson[SUP] 1 [/SUP], Alyssa A Pullano[SUP] 1 [/SUP], Lyuba Bolkhovitinov[SUP] 1 [/SUP], Breanna Kim[SUP] 1 [/SUP], Isabel Steinberg[SUP] 1 [/SUP], Trevor Griesman[SUP] 1 [/SUP], Sarah Stuccio[SUP] 1 [/SUP], Daniel Rogan[SUP] 1 [/SUP], Andy Patamawenu[SUP] 1 [/SUP], Tulley Shofner[SUP] 1 [/SUP], Nathaniel E Wright[SUP] 1 [/SUP], Jonathan D Webber[SUP] 1 [/SUP], Freya Van't Veer[SUP] 1 [/SUP], Rachel Roenicke[SUP] 1 [/SUP], Emma Koory[SUP] 1 [/SUP], Peyton M Roeder[SUP] 1 [/SUP], Ellison Ober[SUP] 1 [/SUP], Benjamin Leach[SUP] 1 [/SUP], Yaroslav Tsybovsky[SUP] 2 [/SUP], Tyler Stephens[SUP] 2 [/SUP], Ivan Del Moral-Sanchez[SUP] 3 [/SUP], Ilja Bontjer[SUP] 3 [/SUP], Lori W McGinnes-Cullen[SUP] 4 [/SUP], Eric Chu[SUP] 5 [/SUP], Jason Liang[SUP] 5 [/SUP], Jonathan L Torres[SUP] 6 [/SUP], Ryan N Lin[SUP] 6 [/SUP], Andy S Tran[SUP] 6 [/SUP], Gabrielle Dziubla[SUP] 7 [/SUP], Leonid Serebryannyy[SUP] 7 [/SUP], Sandeep Narpala[SUP] 7 [/SUP], Bob Lin[SUP] 7 [/SUP], Mike Castro[SUP] 7 [/SUP], Gabriel Ozorowski[SUP] 6 [/SUP], Andrew B Ward[SUP] 6 [/SUP], Rogier W Sanders[SUP] 3 [/SUP], Peter D Kwong[SUP] 7 [/SUP], Javier Guenaga[SUP] 8 [/SUP], Richard Wyatt[SUP] 8 [/SUP], Trudy Morrison[SUP] 4 [/SUP], Mark Connors[SUP] 9 [/SUP]



Affiliations
Abstract

HIV-1 Env glycoprotein (Env) immunogenicity is limited in part by structural instability and extensive glycan shielding and is likely the greatest obstacle to an HIV-1 vaccine. Stabilized Env trimers can elicit serum neutralizing antibodies, but the response is short-lived. Here we use Newcastle Disease Virus-like particle (NDV-VLP) platform to present stabilized versions of HIV-1 Env at high valency and in the context of varied conformational stability, adjuvants, dose, and antigen persistence. Influenza virus hemagglutinin, or SARS-CoV2 Spike-bearing VLPs rapidly induce neutralizing antibodies, in contrast, they were not induced by those bearing Env. A replicating adenovirus type 4 expressing Env rapidly induces autologous neutralizing antibodies. However, durable neutralizing antibodies are induced only when multiple features of a replicating virus infection are combined, with the largest impact from dose and escalating dose. In summary, we show here immunogenicity of HIV-1 Env could be improved by reproducing features of virus infection.


 
Back
Top